Fusion Pharmaceuticals Inc. Long-Term Debt, Maturity, Year Three
Fusion Pharmaceuticals Inc. had Long-Term Debt, Maturity, Year Three of $18.26 million as of 2023-12-31, per its 10-K filed 2024-03-20.
Discontinued › Notes › Commitment and Contingencies › Long-Term Debt, Fiscal Year Maturity › Long-Term Debt, Maturity, Year Two and Three
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree · last filed 2024-05-07
- 2023-12-31: Long-Term Debt, Maturity, Year Three $18.26M.
- 2023-09-30: Long-Term Debt, Maturity, Year Three $8.70M; Long-Term Debt, Maturity, Year Three as first filed $18.26M.
- 2023-06-30: Long-Term Debt, Maturity, Year Three $18.26M.
- 2023-03-31: Long-Term Debt, Maturity, Year Three $18.26M.
| Period end | Long-Term Debt, Maturity, Year Three | Long-Term Debt, Maturity, Year Three as first filed |
|---|---|---|
| 2023-12-31 | $18.26M 10-K · filed 2024-03-20 | |
| 2023-09-30 | $8.70M 10-Q · filed 2024-05-07 | $18.26M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $18.26M 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $18.26M 10-Q · filed 2023-05-11 | |
| 2022-12-31 | $10.65M 10-K · filed 2023-03-16 | |
| 2022-09-30 | $10.65M 10-Q · filed 2022-11-08 | |
| 2022-06-30 | $3.04M 10-Q · filed 2022-08-09 |